Oppenheimer Initiates Coverage On Vanda Pharmaceuticals with Outperform Rating, Announces Price Target of $10

Benzinga · 3d ago
Oppenheimer analyst Les Sulewski initiates coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) with a Outperform rating and announces Price Target of $10.